NIH Highlighted Topic: Postnatal Human Developmental Stages and Transitions: Relationships to Aging Changes and Outcomes over the Life Course
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals focused on understanding how postnatal developmental stages and biological transitions influence health, resilience, disease risk, and aging outcomes across the lifespan. This highlighted topic supports multidisciplinary projects investigating how physiological, metabolic, immune, neurobehavioral, and regenerative processes during childhood, adolescence, and maturation shape long-term functional capacity, chronic disease susceptibility, and healthy aging trajectories.
NIH is particularly interested in projects exploring how developmental timing, stage transitions, and biological plasticity influence protective phenotypes, stress responses, tissue repair, cognitive health, immune function, and metabolic regulation. Companies developing AI-enabled developmental analytics platforms, biomarker discovery systems, digital health monitoring tools, longitudinal health modeling technologies, neurodevelopmental assessment systems, precision aging platforms, or resilience-focused therapeutics may be strong candidates for funding.
Areas of interest include immune and endocrine maturation, neurodevelopment, metabolic programming, stress-response systems, regenerative biology, developmental biomarkers, sex differences, resilience mechanisms, cancer and aging interactions, complementary and integrative health approaches, nutritional influences, and translational interventions capable of sustaining or mimicking favorable developmental phenotypes into adulthood and aging. NIH is also encouraging projects using longitudinal cohort data, computational biology, multi-omics technologies, digital phenotyping, and translational model systems to improve understanding of life-course health trajectories.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.
This highlighted topic is supported by multiple NIH Institutes and Offices including NIA, NCCIH, NCI, ECHO, OBSSR, and ONR, all of which are seeking transformative innovations that improve developmental health research, resilience science, aging biology, neurodevelopment, disease prevention, and life-course precision health strategies.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of developmental health technologies, biomarker systems, AI analytics platforms, longitudinal monitoring tools, resilience-focused interventions, and precision aging solutions.
Eligible activities may include:
AI and machine learning platforms for developmental trajectory and aging-risk prediction
Biomarker discovery and validation systems for maturational transitions and resilience
Longitudinal developmental and life-course health analytics platforms
Neurodevelopmental, cognitive, and behavioral assessment technologies
Immune, endocrine, and metabolic maturation monitoring systems
Regenerative biology and tissue-repair research technologies
Digital phenotyping and wearable monitoring systems for youth and aging populations
Precision health and resilience-focused intervention platforms
Computational biology and systems modeling for developmental and aging research
Sex-specific developmental and disease-risk analytics technologies
Nutritional status and developmental metabolism assessment platforms
Complementary and integrative health intervention technologies for emotional resilience
Cancer survivorship and treatment-related aging trajectory monitoring systems
Stress-response and psychophysiological regulation analytics platforms
Multi-omics, exposome, and environmental influence modeling technologies
Translational therapeutics designed to sustain or mimic favorable developmental phenotypes
Prototype development, translational studies, and longitudinal validation research
Commercialization planning, regulatory preparation, and implementation scaling activities
Funding may also support personnel, software engineering, cloud infrastructure, AI model development, bioinformatics analysis, wearable integration, longitudinal cohort analysis, clinical research, biomarker testing, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable developmental health or precision aging solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
